Tracking Antineoplastic Hazards in Hospitals with ChemoAlert

Dana-Farber Cancer Institute is one of the world’s leading providers of cancer research and care. Their opening of a new care center in 2011 provided a unique opportunity to investigate residual surface contamination related to the formulation and administration of antineoplastic drugs used in chemotherapy. Learn how Bureau Veritas performed product development, provided a single swab to test multiple drugs and conducted analysis to meet the needs of Dana-Farber’s sampling program.

Please fill in your contact information to receive an email with a PDF copy of the case study.